Provectus announced today that it has begun treating its first patient and is recruiting patients for the Phase 2 clinical trial of topical PH-10, which is designed to treat psoriasis.
The study will assess the effectiveness of topically applied PH-10 in twenty-five participants. The medication will be administered twice a week for up to twelve weeks. The entire study is taking place at the Mount Sinai School of Medicine in New York and is anticipated to take nine months to complete.
Craig Dees, Ph.D., CEO of Provectus, stated, “We are pleased to offer patients with moderate to severe psoriasis the opportunity to participate in the Phase 2 clinical trial of PH-10, which we hope will prove to be more efficacious and safer than currently existing products,”
He continued to say, “If the study proves to be as successful as we expect, topical PH-10 could be extremely advantageous in the treatment of psoriasis, a large underserved market in which current, highly expensive treatments may be efficacious but have a number of side effects including infections and risk of cancer.”
Let us hear your thoughts: Provectus Pharmaceuticals, Inc. Message Board